Liponex suffers increased losses

Liponex Inc. takes a $865,260 hit in Q2, as the biopharmaceutical company continues to see net losses related to ongoing testing and reformulation of its “good cholesterol” drug candidate CRD5. Liponex, which is still in the development stage, did not post any revenues for the quarter. Bill Dickie, Liponex CEO, notes that recent animal testing for the new formulation of CRD5 has not provided definitive results, and that more time and funding will be needed for follow-on human trials.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN